Andrew Gengos, CFO and Chief Business Officer at Athira Pharma, Inc. (ATHA), sold 1,272 shares at $0.57 ($725) on 2024-09-05, disclosed to the SEC on 2024-09-05.
Open-market sale of $725 ATHA by CFO and Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ATHA | SELL | 2024-02-16 | $4K | — | Filing → |
| ATHA | SELL | 2024-01-08 | $4K | — | Filing → |
| ATHA | BUY | 2023-06-09 | $51K | — | Filing → |